Endoscopy
Signal score, how each part rates
ActionabilityPrevalenceStakesEvidence strengthNovelty
See the full rubric →Diagnostic Performance and Feasibility of the CC100 Colon Capsule Endoscopy System: A Prospective Multicenter Study.
Clinical takeawayConsider CC100 colon capsule endoscopy as a minimally invasive alternative for colorectal cancer screening in average-risk patients aged 45+ who decline or are unsuitable for conventional colonoscopy, given its high specificity for polyps ≥6 mm. No clinical action yet for routine use over colonoscopy due to lower sensitivity and incomplete visualization in 8.82%.
What it foundCC100 colon capsule endoscopy achieved complete colonic visualization in 91.18% (124/136) of participants and showed 86.67% sensitivity and 98.63% specificity for detecting polyps ≥6 mm compared to conventional colonoscopy. No capsule retention or procedure-related adverse events occurred.
ContextChallenges current reliance on colonoscopy by offering a less invasive option with reasonable accuracy, though colonoscopy remains the gold standard for completeness and sensitivity.
Emergingsuggested applicable standard· U.S. Multi-Society Task Force on Colorectal Cancer (Rex DK, Boland CR, Dominitz JA, et al.), "Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer," Gastroenterology, 2017
Decision at stakewhether colon capsule endoscopy is a viable alternative for colorectal cancer screening
U.S. Multi-Society Task Force on Colorectal Cancer (Rex DK, Boland CR, Dominitz JA, et al.), "Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer," Gastroenterology, 2017 · reviewed 2026-07-23 ↗Begin average-risk colorectal cancer screening at age 45 using a patient-centered shared-decision modality choice, colonoscopy every 10 years (preferred) or annual FIT as Tier 1 options, with multi-target stool DNA every 3 years, CT colonography every 5 years, or flexible sigmoidoscopy every 5 to 10 years as Tier 2 alternatives. A positive stool-based test requires diagnostic colonoscopy, and stool tests should not be ordered for patients who would decline follow-up colonoscopy. Generally stop at age 75 with individualized decisions for ages 76-85 and no screening beyond 85.
Xie X … Yang S · Gastrointestinal Endoscopy · IF 8.0 · PubMed ↗